PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för selinexor. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

43 hits

Bibliografisk träff 2024-03-08

Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.

Babar A, Babar M, Zubair H, Shahid A, Rafique S, Bano M, Waleed MS, Khan M, Inayat A, Safi D.

J Oncol Pharm Pract · review; journal article · DOI 10.1177/10781552241235902

Bibliografisk träff 2024-01-05

Treatment of multiple myeloma with selinexor: a review.

Huang Q, Zhao R, Xu L, Hao X, Tao S.

Ther Adv Hematol · review-article; review; journal article · DOI 10.1177/20406207231219442

Bibliografisk träff 2023-12-18

Discovery of a Hidden Pocket beneath the NES Groove by Novel Noncovalent CRM1 Inhibitors.

Li C, Zhang Q, Huang W, Huang L, Long Q, Lei Y, Jia D, Yang S, Yang Y, Zhang X, Sun Q.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c01867

Bibliografisk träff 2023-11-10

Nuclear transport proteins: structure, function, and disease relevance.

Yang Y, Guo L, Chen L, Gong B, Jia D, Sun Q.

Signal Transduct Target Ther · review-article; review; journal article · DOI 10.1038/s41392-023-01649-4

Bibliografisk träff 2023-09-15

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma.

Mittal S, Kadamberi IP, Chang H, Wang F, Kumar S, Tsaih SW, Walker CJ, Chaluvally-Raghavan P, Charlson J, Landesman Y, Pradeep S.

Exp Hematol Oncol · letter · DOI 10.1186/s40164-023-00443-w

Bibliografisk träff 2023-09-13

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice.

Stiff PJ, Mehrotra S, Potkul RK, Banerjee S, Walker C, Drakes ML.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers15184541

Bibliografisk träff 2023-08-18

Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors.

Jian L, Zscherp R, Beutling U, Shen X, Xu S, Zhang X, Brönstrup M, Klahn P, Sun Q.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c00549

Bibliografisk träff 2023-07-01

Effect of selinexor on lipogenesis in virus-positive Merkel cell carcinoma cell lines.

Landes JR, Bartley BR, Moore SA, He Q, Simonette R, Rady PL, Doan HQ, Tyring SK.

Clin Exp Dermatol · journal article · DOI 10.1093/ced/llad081

Bibliografisk träff 2023-06-01

Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects.

Li S, Fu J, Walker CJ, Yang J, Bhutani D, Chakraborty R, Mamillapalli N, Mapara MY, Landesman Y, Lentzsch S.

Blood Adv · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/bloodadvances.2021006638

Bibliografisk träff 2023-05-16

Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells.

Xu J, Wu S, Li G.

Exp Ther Med · research-article; journal article · DOI 10.3892/etm.2023.12025

Bibliografisk träff 2023-05-01

Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis.

Camilli S, Lockey R, Kolliputi N.

Cell Biochem Biophys · review; journal article · DOI 10.1007/s12013-023-01135-2

Bibliografisk träff 2023-04-29

Selinexor

Författaruppgift saknas

Journal missing · review

Bibliografisk träff 2023-04-27

Development of Erf-Mediated Craniosynostosis and Pharmacological Amelioration.

Vogiatzi A, Keklikoglou K, Makris K, Argyrou DS, Zacharopoulos A, Sotiropoulou V, Parthenios N, Gkikas A, Kokkori M, Richardson MSW, Fenwick AL, Archontidi S, Arvanitidis C, Robertson J, Parthenios J, Zacharakis G, Twigg SRF, Wilkie AOM, Mavrothalassitis G.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms24097961

Bibliografisk träff 2023-04-20

Enhance Mitochondrial Damage by Nuclear Export Inhibition to Suppress Tumor Growth and Metastasis with Increased Antitumor Properties of Macrophages.

Yao Y, Tao J, Lyu J, Chen C, Huang Y, Zhou Z.

ACS Appl Mater Interfaces · journal article · DOI 10.1021/acsami.3c02305

Bibliografisk träff 2023-04-06

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling.

Long H, Hou Y, Li J, Song C, Ge Z.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms24076816

Bibliografisk träff 2023-04-04

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.

Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F.

Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1002/cncr.34773

Bibliografisk träff 2023-03-27

High Throughput Fluorescence-Based In Vitro Experimental Platform for the Identification of Effective Therapies to Overcome Tumour Microenvironment-Mediated Drug Resistance in AML.

Arroyo-Berdugo Y, Sendino M, Greaves D, Nojszewska N, Idilli O, So CW, Di Silvio L, Quartey-Papafio R, Farzaneh F, Rodriguez JA, Calle Y.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers15071988

Bibliografisk träff 2023-03-20

KPT-330 and Y219 exert a synergistic antitumor effect in triple-negative breast cancer through inhibiting NF-κB signaling.

Wen T, Geng M, Bai E, Wang X, Miao H, Chen Z, Zhou H, Wang J, Shi J, Zhang Y, Lei M, Zhu Y.

FEBS Open Bio · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/2211-5463.13588

Bibliografisk träff 2023-03-01

Interference with XPO1 Suppresses the Stemness and Radioresistance of CD44 Positive Cervical Cancer Cells via Binding with Rad21.

Song G, Ren J, Li Y, Cui J.

Ann Clin Lab Sci · journal article

Bibliografisk träff 2023-01-31

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.

Kwanten B, Deconick T, Walker C, Wang F, Landesman Y, Daelemans D.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2023.114305

Bibliografisk träff 2023-01-09

Searching for Novel Noncovalent Nuclear Export Inhibitors through a Drug Repurposing Approach.

Huang W, Wang JX, Shen X, Lei Y, Chen X, Jia D, Zhang X, Sun Q.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c01772

Bibliografisk träff 2022-10-05

Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation.

Zhao C, Ma B, Yang ZY, Li O, Liu SL, Pan LJ, Gong W, Dong P, Shu YJ.

Cancer Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cam4.5322

Bibliografisk träff 2022-09-30

Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.

Zhao C, Yang ZY, Zhang J, Li O, Liu SL, Cai C, Shu YJ, Pan LJ, Gong W, Dong P.

J Transl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12967-022-03635-w

Bibliografisk träff 2022-08-08

The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.

Landes JR, Moore SA, Bartley BR, Doan HQ, Rady PL, Tyring SK.

J Cancer Res Clin Oncol · review-article; review; journal article · DOI 10.1007/s00432-022-04247-z

Bibliografisk träff 2022-06-03

Nuclear Export Inhibition for Radiosensitization: A Proof-of-Concept Phase 1 Clinical Trial of Selinexor (KPT-330) Combined With Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.

Lawrence YR, Shacham-Shmueli E, Yarom N, Khaikin M, Venturero M, Apter S, Inbar Y, Symon Z, Aderka D, Halpern N, Berger R, Boursi B, Jacobson G, Raskin S, Ackerstein A, Margalit O, Appel S, Schvimer M, Crochiere M, Yang F, Landesman Y, Rashal T, Shacham S, Golan T.

Int J Radiat Oncol Biol Phys · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1016/j.ijrobp.2022.05.026

Bibliografisk träff 2022-04-28

Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.

Ishikawa C, Mori N.

Invest New Drugs · research support, non-u.s. gov't; journal article · DOI 10.1007/s10637-022-01250-6

Bibliografisk träff 2022-03-31

Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia.

Yu H, Wu S, Liu S, Li X, Gai Y, Lin H, Wang Y, Edwards H, Ge Y, Wang G.

J Cell Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/jcmm.17274

Bibliografisk träff 2021-11-05

Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.

Suzuki R, Kitamura Y, Ogiya D, Ogawa Y, Kawada H, Ando K.

Int J Hematol · journal article · DOI 10.1007/s12185-021-03244-1

Bibliografisk träff 2021-10-20

Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.

Liu S, Qiao W, Sun Q, Luo Y.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.1c01145

Bibliografisk träff 2021-09-06

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.

Tremblay G, Daniele P, Breeze J, Li L, Shah J, Shacham S, Kauffman M, Engelhardt M, Chari A, Nooka A, Vogl D, Gavriatopoulou M, Dimopoulos MA, Richardson P, Biran N, Siegel D, Vlummens P, Doyen C, Facon T, Mohty M, Meuleman N, Levy M, Costa L, Hoffman JE, Delforge M, Kaminetzky D, Weisel K, Raab M, Dingli D, Tuchman S, Laurent F, Vij R, Schiller G, Moreau P, Richter J, Schreder M, Podar K, Parker T, Cornell RF, Lionel K, Choquet S, Sundar J.

BMC Cancer · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.1186/s12885-021-08453-9